tiprankstipranks
Trending News
More News >

Lantern Pharma Reports Q1 2025 Financial Results

Story Highlights
  • Lantern Pharma completed LP-184 Phase 1a trial enrollment and plans data readouts for LP-300 in Q3 2025.
  • The company expanded its RADR® platform and plans to launch AI modules for cancer drug development.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Lantern Pharma Reports Q1 2025 Financial Results

Confident Investing Starts Here:

Lantern Pharma ( (LTRN) ) has issued an announcement.

Lantern Pharma announced its first quarter 2025 financial results and business updates, highlighting key advancements in its AI-driven drug development pipeline. The company completed enrollment for its LP-184 Phase 1a clinical trial and anticipates additional data readouts for its LP-300 HARMONIC™ Trial in Q3 2025. Lantern has expanded its RADR® platform with new AI-powered modules to enhance antibody-drug conjugate development and is planning the commercial launch of select AI modules for the scientific community. The company also reported maintaining disciplined capital management with $19.7 million in cash and equivalents, providing an operating runway through May 2026.

The most recent analyst rating on (LTRN) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Lantern Pharma stock, see the LTRN Stock Forecast page.

Spark’s Take on LTRN Stock

According to Spark, TipRanks’ AI Analyst, LTRN is a Neutral.

Lantern Pharma is innovating with AI in oncology, achieving key clinical and regulatory milestones. However, the financial outlook is challenging due to zero revenue and cash flow concerns, necessitating additional funding. Technicals are stable but show potential volatility.

To see Spark’s full report on LTRN stock, click here.

More about Lantern Pharma

Lantern Pharma Inc. is a clinical-stage biopharmaceutical company that leverages its proprietary RADR® artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development.

Average Trading Volume: 40,003

Technical Sentiment Signal: Hold

Current Market Cap: $44.33M

For an in-depth examination of LTRN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1